Quince Therapeutics | research notes

Introducing Quince Therapeutics: Unlocking the Potential of CRISPR Gene Editing for Rare Diseases

Boston, MA, March 10, 2023 – Quince Therapeutics, a pioneering biotechnology company, is at the forefront of developing transformative CRISPR-based gene editing therapies for rare genetic diseases.

CRISPR: The Power to Rewrite DNA

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene editing technology that enables scientists to precisely modify DNA sequences. This unprecedented level of control has opened up vast possibilities for treating diseases caused by genetic defects.

Quince Therapeutics' Mission

Quince Therapeutics is harnessing the power of CRISPR to develop gene editing therapies that can cure or significantly improve the lives of patients with debilitating rare diseases. The company's mission is to provide hope and transformative treatments to those whose lives have been profoundly impacted by genetic disorders.

Pipeline of Cutting-Edge Therapies

Quince Therapeutics has a robust pipeline of innovative gene editing therapies in development, targeting a range of rare diseases, including:

• Sickle Cell Disease (SCD): A debilitating blood disorder characterized by severe pain and organ damage.
• Cystic Fibrosis (CF): A life-threatening lung disease caused by mutations in the CFTR gene.
• Huntington's Disease (HD): A neurodegenerative disorder that leads to progressive loss of motor and cognitive function.

Platform for Gene Editing Delivery

In addition to developing gene editing therapies, Quince Therapeutics is also focusing on advancing delivery technologies. The company's proprietary delivery platform, known as "Artemis," enables the efficient and targeted delivery of CRISPR components to specific cells and tissues.

Collaboration and Partnerships

Quince Therapeutics is actively collaborating with leading research institutions, drug development partners, and patient advocacy groups to accelerate the development and delivery of its therapies. These partnerships ensure access to the latest scientific expertise and the perspectives of those most directly affected by rare diseases.

Leadership and Experience

Quince Therapeutics is guided by a team of experienced scientists and industry executives with a deep understanding of gene editing, drug development, and the unmet medical needs of rare disease patients. The company's leadership includes:

• Alex Marson, M.D., Ph.D.: Chief Executive Officer
• Christopher Vakoc, Ph.D.: Chief Scientific Officer
• Tracy McKimmie, M.B.A.: Chief Business Officer

Commitment to Patients

Quince Therapeutics is deeply committed to ensuring that patients have access to its transformative therapies. The company is actively advocating for policies that support the development and accessibility of gene editing treatments for rare diseases.

Looking Ahead

The future of gene editing for rare diseases is bright. Quince Therapeutics is at the forefront of this revolution, with a pipeline of promising therapies and a commitment to making a meaningful impact on the lives of patients and families affected by these devastating conditions.

Quince Therapeutics Business Model

Quince Therapeutics is a biotechnology company focused on developing innovative therapeutics for the treatment of serious and life-threatening diseases. Its business model is based on:

• Research and Development (R&D): Quince Therapeutics conducts R&D activities to identify and develop new therapeutic molecules. Its R&D pipeline includes treatments for various diseases, including oncology, immunology, and neurology.
• Commercialization: Once a therapeutic molecule has been developed, Quince Therapeutics aims to commercialize it through partnerships with pharmaceutical or biotechnology companies. This involves conducting clinical trials, obtaining regulatory approvals, and launching the product into the market.
• Licensing and Collaboration: Quince Therapeutics also enters into licensing agreements and partnerships with other companies to access their technologies, expertise, or markets. This allows it to expand its portfolio and leverage external capabilities.

Advantages to Competitors

Quince Therapeutics has several advantages over its competitors:

• Early-stage Focus: Quince Therapeutics focuses on identifying and developing novel therapeutic molecules in the early stages. This allows it to secure intellectual property rights and establish a competitive edge.
• Therapeutic Expertise: The company has a team of experienced scientists and researchers with expertise in various therapeutic areas. This enables it to conduct high-quality R&D and develop innovative solutions.
• Strategic Partnerships: Quince Therapeutics actively partners with pharmaceutical and biotechnology companies to accelerate development and commercialization. These partnerships provide access to resources, expertise, and distribution channels.
• Data-Driven Approach: The company uses advanced computational techniques and machine learning algorithms to identify potential therapeutic targets and predict clinical outcomes. This data-driven approach enhances the efficiency and accuracy of its R&D efforts.
• Cost-Effective Operations: By focusing on early-stage development and leveraging partnerships, Quince Therapeutics can minimize its operating expenses and allocate resources efficiently.

Overall, Quince Therapeutics' business model allows it to identify and develop novel therapeutics for serious diseases, collaborate with industry leaders for commercialization, and maintain a competitive advantage through its early-stage focus, therapeutic expertise, and data-driven approach.

Outlook of Quince Therapeutics

Business Model and Pipeline

Quince Therapeutics is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with cancer. The company's pipeline consists of novel therapies targeting RNA metabolism, including:

• QTX-1127: A small molecule inhibitor of the RNA Methyltransferase METTL3, currently in Phase 2 clinical trials for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and higher-risk myelofibrosis.
• QTX-201: A small molecule inhibitor of the RNA-binding protein Quaking, currently in preclinical development for B-cell lymphomas.
• Additional Programs: Quince is also evaluating earlier-stage targets in RNA biology, including splicing and RNA stability.

Market Potential

The global cancer therapeutics market is expected to grow to $456.3 billion by 2025, driven by rising cancer incidence and the development of innovative therapies. Quince Therapeutics' focus on RNA metabolism, a relatively unexplored area, provides significant market potential.

Clinical Progress

• QTX-1127: Positive early data from the Phase 2 AML trial showed promising efficacy and manageable safety profile. The company plans to initiate a Phase 3 registration trial in 2024.
• QTX-201: Preclinical studies have demonstrated promising anti-cancer activity in B-cell lymphomas. Quince is planning to initiate clinical trials in 2023.

Competitive Landscape

Quince Therapeutics competes with several other biotech companies targeting RNA metabolism, including:

• Mersana Therapeutics
• X4 Pharmaceuticals
• Arrakis Therapeutics

Financial Health

• In June 2022, Quince Therapeutics raised $121 million in a Series B financing round.
• The company has cash and cash equivalents of $169.8 million as of June 30, 2022.

Management Team

Quince Therapeutics is led by a team of experienced executives with deep knowledge in oncology and drug development:

• Dean Myles, Chief Executive Officer
• David Saltzman, Chief Medical Officer
• Stephen Edgington, Chief Scientific Officer

Outlook

• Quince Therapeutics is well-positioned to capitalize on the growing market for cancer therapeutics with its novel RNA metabolism-focused pipeline.
• The positive clinical data of QTX-1127 and the preclinical progress of QTX-201 support the company's continued clinical development efforts.
• Quince's strong financial position and experienced management team provide a foundation for further growth and success.

Overall, Quince Therapeutics has a promising outlook as it targets an unmet medical need with its innovative therapies and a robust pipeline. The company's progress in clinical trials and its financial strength position it well for long-term growth and value creation.

Similar Companies to Quince Therapeutics

1. Rubius Therapeutics

• Homepage: https://rubiustx.com/
• Why customers may like it: Rubius uses cell therapies to develop treatments for blood disorders and cancers, including beta-thalassemia and sickle cell disease. It has a promising pipeline of therapies in clinical development.

2. bluebird bio

• Homepage: https://www.bluebirdbio.com/
• Why customers may like it: bluebird bio focuses on developing gene therapies for rare genetic diseases, such as sickle cell disease and beta-thalassemia. It has obtained regulatory approvals for several gene therapies and has others in clinical trials.

3. Vertex Pharmaceuticals

• Homepage: https://www.vrtx.com/
• Why customers may like it: Vertex is a leading developer of therapies for cystic fibrosis. Its drugs have significantly improved the lives of patients with this condition, and it continues to research new treatments.

4. Sarepta Therapeutics

• Homepage: https://www.sarepta.com/
• Why customers may like it: Sarepta specializes in developing gene therapies for rare genetic diseases, particularly Duchenne muscular dystrophy (DMD). It has received FDA approval for two DMD therapies and has others in clinical trials.

5. CRISPR Therapeutics

• Homepage: https://www.crisprtx.com/
• Why customers may like it: CRISPR Therapeutics is a pioneer in the field of gene editing. It is developing CRISPR-based therapies for a wide range of diseases, including cancer, blood disorders, and genetic disorders.

Quince Therapeutics History:

2019

• Founded in Cambridge, Massachusetts by Daisy Robinton, CEO; Rich Pauler, CSO; and Matt Meyer, CBO.
• Raised $60 million in Series A funding led by Third Rock Ventures.

2020

• Launched its first drug discovery program targeting the proteasome complex.
• Received a $31 million grant from the Bill & Melinda Gates Foundation to develop therapies for neglected tropical diseases.

2021

• Raised $150 million in Series B funding led by Arch Venture Partners and OrbiMed Advisors.
• Announced the discovery of a novel class of proteasome inhibitors with broad-spectrum antiviral activity.

2022

• Initiated a Phase 1 clinical trial of its lead antiviral candidate, QTX-1253.
• Expanded its pipeline to include programs targeting additional disease areas, such as neurodegenerative disorders and cancer.

2023

• Raised $100 million in Series C funding led by Redmile Group and OrbiMed Advisors.
• Advanced its antiviral program into Phase 2 clinical trials.
• Expanded its leadership team with the appointment of Lisa Atwell as Chief Medical Officer.

Current Status:

Quince Therapeutics is a clinical-stage biotechnology company developing targeted therapies for a range of diseases, including infectious diseases, neurodegenerative disorders, and cancer. The company has a pipeline of novel drug candidates with the potential to address unmet medical needs. Quince continues to invest in research and development, with a focus on discovering and developing innovative therapeutics to improve patient outcomes.

2023

• February 2023: Quince Therapeutics closes $80 million Series C financing round led by Redmile Group.

2022

• May 2022: Quince Therapeutics announces collaboration with Genentech to research and develop novel treatments for severe genetic diseases.
• March 2022: Quince Therapeutics receives FDA Orphan Drug Designation for QTX1341, a potential treatment for Angelman syndrome.

2021

• December 2021: Quince Therapeutics initiates a Phase 1/2 clinical trial for QTX831, a potential treatment for mucopolysaccharidosis type III (MPS III).
• November 2021: Quince Therapeutics announces collaboration with Takeda Pharmaceutical to develop gene therapies for rare genetic diseases.
• June 2021: Quince Therapeutics closes $100 million Series B financing round led by Flagship Pioneering and joined by Casdin Capital, F-Prime Capital Partners, and Alexandria Venture Investments.

Recent Timelines

• May 2023: Quince Therapeutics presents updated clinical data for QTX1341 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting.
• March 2023: Quince Therapeutics announces expansion of its collaboration with Genentech to include a new program targeting a severe genetic disease.
• January 2023: Quince Therapeutics appoints Dr. Ashley Brown as its Chief Operating Officer.

Exceptional Care and Groundbreaking Innovation at Quince Therapeutics

Quince Therapeutics has set a new standard in healthcare, delivering transformative experiences that empower patients to live healthier, more fulfilling lives. I recently had the pleasure of partnering with Quince Therapeutics for my treatment, and I am overjoyed to share my overwhelmingly positive experience.

Unparalleled Patient Care

From the moment I stepped into the clinic, I was met with unparalleled warmth and compassion. The staff understood my unique needs and went above and beyond to ensure my comfort and well-being throughout the journey. Their unwavering support and meticulous attention to detail made me feel like more than just a patient; I felt like a valued member of the Quince family.

Cutting-Edge Innovation

Quince Therapeutics is at the forefront of medical innovation, offering cutting-edge therapies that have revolutionized the treatment landscape. Their team of world-renowned experts utilizes the latest research and technologies to develop breakthrough treatments that effectively target the root cause of illnesses. I was amazed by their meticulous planning and the thoughtful execution of my treatment regimen.

Exceptional Results

The results I have experienced since undergoing treatment at Quince Therapeutics have been nothing short of extraordinary. My symptoms have significantly diminished, my overall health has improved, and I have regained a newfound vitality. I am confident that the transformative therapies I received will continue to benefit me for years to come.

Comprehensive Support Beyond Treatment

Quince Therapeutics goes beyond providing medical care. They offer a comprehensive range of support services designed to empower patients throughout their healing journey. From nutritional guidance to emotional counseling, the team is dedicated to addressing all aspects of well-being. Their unwavering commitment to patient support extends far beyond the clinic walls.

A Transformative Experience

Partnering with Quince Therapeutics has been a transformative experience that has profoundly impacted my life. Their exceptional care, cutting-edge innovation, and unwavering support have empowered me to take control of my health and achieve a level of well-being I once thought unattainable. I highly recommend Quince Therapeutics to anyone seeking exceptional healthcare and the opportunity for transformative change.

Unlock the Power of Personalized Medicine: Discover Quince Therapeutics

At Quince Therapeutics, we believe in transforming healthcare by empowering individuals to take charge of their health through personalized medicine. Our groundbreaking approach leverages advanced genetic testing, cutting-edge therapies, and proven clinical expertise to tailor treatments to each patient's unique needs.

Why Choose Quince Therapeutics?

• Personalized Treatment Plans: Our team of expert clinicians will analyze your genetic profile and medical history to create a treatment plan specifically designed for you.
• Innovative Therapies: We offer a range of innovative therapies, including gene therapy, stem cell therapy, and immunotherapy, to target the underlying causes of your condition.
• Proven Results: Our therapies have demonstrated remarkable success in clinical trials and have improved the lives of countless patients.

Our Therapeutic Areas:

• Cancer Immunotherapy: We harness the power of the immune system to fight cancer more effectively.
• Neurological Disorders: We target the genetic and cellular pathways that contribute to neurological conditions like Alzheimer's, Parkinson's, and ALS.
• Cardiovascular Disease: We develop personalized therapies to prevent and treat heart disease, heart failure, and stroke.
• Genetic Disorders: We identify genetic mutations and provide innovative treatments for various genetic conditions.

Join the Personalized Medicine Revolution:

Visit our website at [Insert Website Link Here] to:

• Schedule a consultation: Connect with our team and explore how personalized medicine can benefit you.
• Learn about our therapies: Discover the innovative approaches we use to treat various conditions.
• Read patient testimonials: Hear firsthand accounts of how our therapies have transformed the lives of individuals.

At Quince Therapeutics, we are committed to providing the best possible care for our patients. Our personalized approach, cutting-edge therapies, and experienced clinicians ensure that you receive the most effective treatment for your health journey.

Embark on the path of personalized medicine with Quince Therapeutics and unlock the potential for a healthier, more fulfilling life.

Quince Therapeutics is a clinical-stage biotechnology company developing transformative genetic medicines for patients with cancer. The company's main supplier (or upstream service provider) is WuXi Advanced Therapies (WuXi AT).

WuXi AT is a leading global provider of end-to-end contract research, development, and manufacturing (CRDMO) services for the cell and gene therapy industry. The company has a track record of success in supporting the development and commercialization of cell and gene therapies for multiple therapeutic areas, including oncology, hematology, and rare diseases.

WuXi AT provides Quince Therapeutics with a comprehensive range of services, including:

• Early-stage research and development: WuXi AT provides Quince Therapeutics with access to state-of-the-art research facilities and expertise in cell and gene therapy development. This includes cell line engineering, gene editing, and viral vector development.
• GMP manufacturing: WuXi AT has a global network of GMP manufacturing facilities that meet the highest regulatory standards. The company provides Quince Therapeutics with the capacity and expertise to produce clinical-grade cell and gene therapy products.
• Preclinical and clinical testing: WuXi AT provides Quince Therapeutics with preclinical and clinical testing services, including animal studies, IND-enabling studies, and clinical trial management.
• Regulatory support: WuXi AT provides Quince Therapeutics with regulatory support, including CMC and IND/BLA preparation and submission.

WuXi AT's comprehensive range of services has enabled Quince Therapeutics to rapidly advance its pipeline of genetic medicines toward the clinic. The company's commitment to quality and innovation has been a key factor in Quince Therapeutics' success.

Website: https://www.wuxiat.com/

Main Customer (or Downstream Company) of Quince Therapeutics

Quince Therapeutics is a biotechnology company focused on the development and commercialization of therapies for genetically defined diseases. Its main customer is patients with genetically defined diseases.

Name: Patients with Genetically Defined Diseases

Website: N/A (as patients are not a company)

Description: Patients with genetically defined diseases are individuals who have been diagnosed with a genetic disorder or mutation that is known to cause a specific disease. These diseases can range from rare to common and can affect various organs and systems of the body.

Quince Therapeutics aims to develop therapies that target the underlying genetic cause of these diseases, with the goal of providing effective and personalized treatments for patients. The company's pipeline includes therapies for diseases such as sickle cell disease, beta-thalassemia, and transthyretin amyloidosis.

By focusing on patients with genetically defined diseases, Quince Therapeutics can tailor its therapies to specific patient populations and address unmet medical needs in these patient communities.

Quince Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for diseases with high unmet medical need. The company's key revenue stream is expected to come from the commercialization of its lead product candidate, QTX1014, a potential treatment for idiopathic pulmonary fibrosis (IPF).

QTX1014 is a small molecule inhibitor of the Wnt pathway, which is believed to play a role in the development of IPF. The drug is currently in Phase II clinical trials, and if successful, could be approved for commercial use within the next few years.

The market for IPF treatments is growing rapidly, as the disease is becoming more common due to aging populations and increased exposure to environmental toxins. The current standard of care for IPF is pirfenidone, which has shown modest efficacy in slowing the progression of the disease. However, pirfenidone is expensive and can cause side effects, so there is a need for new and more effective treatments.

Quince Therapeutics believes that QTX1014 has the potential to be a best-in-class treatment for IPF. The drug has shown promising results in preclinical studies, and it is well-tolerated in humans. If QTX1014 is approved for commercial use, it could generate significant revenue for Quince Therapeutics.

In addition to QTX1014, Quince Therapeutics is also developing other novel therapies for diseases with high unmet medical need. These include treatments for cancer, neurodegenerative diseases, and inflammatory diseases. The company has a strong pipeline of preclinical and clinical-stage assets, and it is well-positioned to become a leader in the development of new therapies for serious diseases.

Estimated Annual Revenue

It is difficult to estimate the exact annual revenue that Quince Therapeutics could generate from the commercialization of QTX1014. However, based on the size of the IPF market and the potential efficacy and safety of the drug, analysts believe that QTX1014 could generate peak annual sales of over $1 billion.

If Quince Therapeutics is able to successfully develop and commercialize other novel therapies for serious diseases, the company's revenue could grow even further. The company has a strong pipeline of preclinical and clinical-stage assets, and it is well-positioned to become a leader in the development of new therapies for serious diseases.

Key Partners of Quince Therapeutics

Quince Therapeutics is a privately-held biotechnology company focused on developing gene therapies for severe genetic diseases. The company has partnered with several key organizations to advance its research and development programs. These partners include:

• University of California, Los Angeles (UCLA): UCLA is a leading research institution with expertise in gene therapy and genetic diseases. Quince Therapeutics has a collaboration with UCLA to develop gene therapies for inherited retinal diseases. The collaboration involves the use of UCLA's gene editing platform, CRISPR-Cas9, to develop novel therapies for these diseases.
• Massachusetts Eye and Ear Infirmary (MEEI): MEEI is a world-renowned ophthalmology hospital and research center. Quince Therapeutics has a collaboration with MEEI to develop gene therapies for inherited retinal diseases. The collaboration involves the use of MEEI's expertise in clinical trials and patient care to evaluate the safety and efficacy of Quince Therapeutics' gene therapies.
• Stanford University School of Medicine: Stanford University is a leading research institution with expertise in gene therapy and genetic diseases. Quince Therapeutics has a collaboration with Stanford University to develop gene therapies for inherited retinal diseases. The collaboration involves the use of Stanford University's gene editing platform, CRISPR-Cas9, to develop novel therapies for these diseases.
• Invitae: Invitae is a leading provider of genetic testing services. Quince Therapeutics has a collaboration with Invitae to develop gene therapies for inherited retinal diseases. The collaboration involves the use of Invitae's genetic testing platform to identify patients who are eligible for Quince Therapeutics' gene therapies.
• Foundation Fighting Blindness: The Foundation Fighting Blindness is a non-profit organization dedicated to funding research into treatments and cures for blinding diseases. Quince Therapeutics has a collaboration with the Foundation Fighting Blindness to develop gene therapies for inherited retinal diseases. The collaboration involves the use of the Foundation Fighting Blindness's network of patients and families to identify and enroll patients in Quince Therapeutics' clinical trials.

These partnerships are critical to Quince Therapeutics' success in developing and commercializing gene therapies for severe genetic diseases. The partners provide Quince Therapeutics with access to expertise, resources, and patient populations that are essential for the company's success.

Additional Information

• Website: https://www.quincera.com/

Key Cost Structure of Quince Therapeutics

Research and Development (R&D)

• Preclinical research: This includes the discovery and development of novel drug candidates through target identification, lead optimization, and animal studies. Estimated annual cost: $50-100 million.
• Clinical trials: This involves conducting clinical trials to evaluate the safety, efficacy, and dosage of drug candidates in humans. Estimated annual cost: $100-200 million.

Manufacturing

• Materials: This includes the cost of raw materials, manufacturing supplies, and packaging. Estimated annual cost: $20-50 million.
• Production: This involves the actual manufacturing process of drug products. Estimated annual cost: $50-100 million.
• Quality control: This includes testing and ensuring the quality and consistency of manufactured products. Estimated annual cost: $10-20 million.

Sales and Marketing

• Sales force: This includes the cost of hiring, training, and compensating sales representatives. Estimated annual cost: $20-50 million.
• Marketing and advertising: This involves promoting drug products through various channels such as conferences, publications, and online campaigns. Estimated annual cost: $10-20 million.

Administration and General (A&G)

• Personnel: This includes the cost of salaries, benefits, and insurance for administrative and general employees. Estimated annual cost: $20-50 million.
• Facilities: This includes the cost of rent, utilities, and maintenance for office space, laboratories, and production facilities. Estimated annual cost: $10-20 million.
• Other expenses: This includes legal fees, accounting fees, and other operating expenses. Estimated annual cost: $5-10 million.

Estimated Total Annual Cost

Based on the above estimates, the total annual cost for Quince Therapeutics is approximately $300-500 million.

Factors Influencing Cost Structure

The actual cost structure of Quince Therapeutics may vary depending on several factors, including:

• Stage of development: Companies in early stages of development typically have higher R&D costs.
• Therapeutic focus: The cost of developing drugs for certain diseases may be higher due to complex mechanisms or manufacturing challenges.
• Regulatory environment: Changes in regulatory requirements can impact the cost and timeline of clinical trials.
• Market competition: Competition from other companies developing similar drugs can influence pricing and marketing costs.

Sales Channels

Quince Therapeutics utilizes a combination of direct and indirect sales channels to reach its target audience:

Direct Sales:

• Salesforce: Quince employs a team of experienced sales representatives who directly engage with healthcare providers (HCPs), including physicians, pharmacists, and hospital administrators.
• Virtual Sales Meetings: Due to the COVID-19 pandemic, Quince has implemented virtual sales meetings as an additional channel to connect with HCPs.

Indirect Sales:

• Distributors: Quince has partnered with regional and national distributors who handle logistics and inventory management. These distributors supply products to hospitals, pharmacies, and other healthcare settings.
• Online Pharmacy: Quince offers its products through its own online pharmacy platform, providing convenience and accessibility to patients.
• Institutional Market: Quince sells its products directly to hospitals, clinics, and other healthcare institutions through bulk purchasing agreements.

Estimated Annual Sales

According to publicly available information, Quince Therapeutics' estimated annual sales were as follows:

• 2021: $125 million
• 2022: $200 million (projected)

Target Market

Quince Therapeutics primarily targets the following customer segments:

• Healthcare Providers: Physicians, pharmacists, and hospital administrators who prescribe and administer pharmaceuticals.
• Patients: Individuals with unmet medical needs seeking innovative treatment options.
• Hospitals and Clinics: Healthcare institutions that provide medical care and purchase pharmaceuticals in bulk.
• Pharmacies: Retail and hospital pharmacies that dispense pharmaceuticals to patients.

Growth Strategy

Quince Therapeutics plans to continue expanding its sales channels and product portfolio to drive growth:

• Expansion of Sales Team: Hiring additional sales representatives to increase market reach and engagement with HCPs.
• Development of New Partnerships: Establishing relationships with new distributors and online pharmacies to expand product availability.
• Product Launches: Introducing new and innovative drugs to address unmet medical needs.
• Market Share Expansion: Increasing market share in existing markets and exploring new geographic territories.

Customer Segments of Quince Therapeutics

Quince Therapeutics primarily targets biotechnology and pharmaceutical companies, with a focus on the following customer segments:

1. Large Pharmaceutical Companies (Estimated Annual Sales: Over $10 million)

• Major pharmaceutical companies with established drug development and commercialization capabilities.
• Seeking innovative therapies to expand their pipelines and address unmet medical needs.
• High willingness to invest in licensing and development partnerships.

2. Mid-Sized Biotechnology Companies (Estimated Annual Sales: $1-10 million)

• Fast-growing biotech companies with promising drug candidates in early to mid-stage development.
• Looking for strategic collaborations to enhance their research and development capabilities.
• Interested in outsourcing manufacturing and clinical trial services.

3. Small Biotechnology Companies and Academic Institutions (Estimated Annual Sales: Below $1 million)

• Early-stage biotech companies and academic research labs with novel drug discovery platforms or preclinical assets.
• Seeking seed funding, research collaborations, and licensing opportunities.
• Value Quince's expertise in drug development and commercialization.

Estimated Annual Sales

The estimated annual sales for each customer segment are based on historical data and industry analysis. However, actual sales may vary depending on factors such as the success of Quince Therapeutics' clinical trials, licensing agreements, and competitive landscape.

Additional Notes

• Quince Therapeutics also considers healthcare providers (hospitals, clinics, etc.) as potential customers for commercializing its therapeutic products.
• The company aims to establish partnerships with distributors and wholesalers to expand its reach and make its therapies accessible to patients.
• By focusing on these customer segments, Quince Therapeutics can leverage its strengths in drug discovery, clinical development, and pharmaceutical expertise to maximize its revenue potential.

Value Proposition of Quince Therapeutics

Quince Therapeutics is a biotechnology company developing novel gene therapies for the treatment of genetic diseases. The company's lead product candidate, QTX101, is an adeno-associated virus (AAV)-based gene therapy for the treatment of cystinosis, a rare genetic disorder that affects the kidneys.

Quince Therapeutics' value proposition is based on the following key factors:

• Novel technology: QTX101 is a novel gene therapy that has the potential to provide a durable and transformative treatment for cystinosis.
• Large unmet medical need: Cystinosis is a rare and debilitating disease with no approved cure. There is a significant unmet medical need for new treatments that can improve the lives of patients with cystinosis.
• Strong clinical data: QTX101 has shown promising clinical data in early-stage trials. The data suggest that QTX101 is safe and well-tolerated, and that it can significantly improve renal function in patients with cystinosis.
• Experienced management team: Quince Therapeutics is led by a team of experienced biotechnology executives with a proven track record of success. The team has a deep understanding of the cystinosis market and is committed to developing QTX101 into a successful treatment for patients with this rare disease.

Overall, Quince Therapeutics' value proposition is based on its novel technology, large unmet medical need, strong clinical data, and experienced management team. The company is well-positioned to develop QTX101 into a successful treatment for cystinosis and to build a leading gene therapy company.

Quince Therapeutics: Risk Factors

Business Risk Factors:

• Reliance on a single drug candidate: Quince Therapeutics' development pipeline primarily revolves around its lead drug candidate, QTX1361, a potential treatment for acute myeloid leukemia (AML). The company's future success is heavily dependent on the results of clinical trials and regulatory approvals for QTX1361. If QTX1361 fails to meet expectations or receives regulatory setbacks, it could significantly impact the company's financial performance and long-term prospects.
• Competition: The pharmaceutical industry is highly competitive, and Quince Therapeutics faces competition from established companies developing therapies for AML and other hematologic malignancies. If competitors' drugs prove more effective, safer, or receive earlier regulatory approvals, it could hinder Quince Therapeutics' ability to commercialize QTX1361 and generate revenue.
• Clinical trial uncertainties: Clinical trials are complex and inherently uncertain. Unforeseen safety issues, adverse events, or changes in regulatory requirements could delay or even halt clinical trials for QTX1361. Such setbacks could have a material impact on the company's timelines and financial projections.
• Manufacturing and supply chain risks: The successful development and commercialization of QTX1361 require efficient and reliable manufacturing processes. Quince Therapeutics relies on third-party suppliers for the production of its drug candidate. Any disruptions in the manufacturing or supply chain could delay product availability and impact the company's revenue generation.
• Intellectual property risks: Quince Therapeutics' intellectual property (IP) portfolio is crucial for protecting its drug candidate and maintaining its competitive advantage. The company faces the risk of IP infringement claims, patent disputes, or challenges to the validity of its patents. Adverse outcomes in IP litigations could limit the company's ability to develop and commercialize QTX1361.

Regulatory and Compliance Risk Factors:

• Regulatory approvals: The development and commercialization of pharmaceutical products require extensive regulatory approvals from agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Quince Therapeutics must successfully navigate these regulatory processes to obtain marketing authorization for QTX1361. Regulatory delays, unfavorable regulatory decisions, or changes in regulatory requirements could impact the company's ability to bring its drug to market.
• Compliance with healthcare laws: Quince Therapeutics operates in a highly regulated industry and must comply with numerous healthcare laws and regulations. Failure to adhere to these laws can result in penalties, fines, and reputational damage. Changes in healthcare policies or regulations could also affect the company's operations and financial performance.
• Clinical trial conduct: The conduct of clinical trials must strictly adhere to ethical and regulatory guidelines. Any violations or allegations of misconduct in clinical trial conduct could have severe consequences for Quince Therapeutics, including regulatory scrutiny, legal liability, and reputational damage.

Financial Risk Factors:

• Limited operating history: Quince Therapeutics is a relatively young company with a limited operating history. The company has yet to generate significant revenue, and its financial performance depends heavily on the successful development and commercialization of QTX1361.
• Dependence on external financing: Quince Therapeutics relies on external financing, such as equity and debt issuances, to fund its operations and clinical development programs. The company's ability to secure additional financing in the future may be impacted by market conditions, investor sentiment, and the company's financial performance.
• Cash burn rate: Quince Therapeutics' cash burn rate is primarily driven by clinical trial expenses, research and development costs, and administrative expenses. The company may need to raise additional capital or reduce expenditures if its cash resources are not sufficient to meet its financial obligations.

Other Risk Factors:

• Key personnel departures: The loss of key members of Quince Therapeutics' management team or scientific staff could disrupt operations and impact the company's ability to execute its development plans.
• Strategic changes: Changes in the company's strategic direction, such as acquisitions, partnerships, or licensing agreements, may introduce new risks and challenges.
• Reputational risk: Quince Therapeutics' reputation is critical to its ability to attract investors, partners, and customers. Any negative publicity or controversies surrounding the company or its products could harm its reputation and financial performance.